Columbia,
MD,
October
14,
2025
–(PR.com)– Precision
Antibody,
a
recognized
leader
in
custom
monoclonal
antibody
development,
is
pleased
to
announce
its
participation
in
the
19th
Drug
Discovery
Strategic
Summit
(DDSS),
taking
place
October
15–16,
2025,
in
San
Francisco,
California.
The
DDSS
is
an
internationally
recognized
gathering
that
brings
together
biopharma
leaders,
academic
researchers,
and
technology
innovators
to
discuss
new
strategies,
technologies,
and
partnerships
driving
the
future
of
drug
discovery.
As
part
of
the
event,
Dr.
Ginette
Serrero,
CEO
at
Precision
Antibody,
will
deliver
a
featured
presentation
titled:
“Development
of
Fully
Human
Monoclonal
Antibodies
to
Cancer
Targets
and
Their
Application
as
Antibody
Drug
Conjugates.”
With
its
proprietary
platform,
Precision
Antibody
offers
royalty-free
fully
human
monoclonal
antibody
development
in
just
60
days
—
empowering
researchers
to
accelerate
discovery
while
maintaining
complete
ownership
of
their
antibodies.
“Our
mission
has
always
been
to
deliver
antibodies
that
work
right
the
first
time,”
said
Dr.
Serrero.
“We
are
excited
to
share
our
advancements
in
fully
human
monoclonal
antibody
development
at
DDSS
and
highlight
their
growing
impact
in
drug
discovery
and
therapeutic
applications.”
In
addition
to
its
rapid
antibody
development
platform,
Precision
Antibody
is
a
proven
biomarker
antibody
specialist
with
a
strong
track
record
of
success
in
developing
high-quality
biomarker
antibodies.
As
proud
contributors
to
the
National
Cancer
Institute’s
(NCI)
Clinical
Proteomic
Technologies
for
Cancer
(CPTC)
program
through
Leidos,
the
company
has
helped
establish
gold-standard
monoclonal
antibodies
widely
used
in
cancer
biomarker
research.
Precision
Antibody
invites
attendees
of
the
19th
DDSS
to
connect
and
learn
how
its
antibody
solutions
can
accelerate
translational
research,
drug
discovery,
and
therapeutic
development
programs.
About
Precision
Antibody
Founded
in
2000,
Precision
Antibody
is
a
U.S.-based
biotechnology
company
specializing
in
the
rapid
development
of
custom
monoclonal
antibodies.
Known
for
delivering
antibodies
that
work
“right
the
first
time,”
Precision
Antibody
supports
pharmaceutical,
biotech,
academic,
and
government
researchers
worldwide.
With
a
strong
track
record
in
biomarker
antibody
development
and
contributions
to
the
NCI’s
Clinical
Proteomic
Technologies
for
Cancer
(CPTC)
program,
the
company
is
recognized
for
setting
benchmarks
in
antibody
quality
and
reliability.
Media
Contact:
Precision
Antibody
Dr.
Jun
Hayashi
President
Phone:
410-884-4100
Email:
info@precisionantibody.com
Website:
www.precisionantibody.com
Event
Details:
19th
Drug
Discovery
Strategic
Summit
(DDSS)
Dates:
October
15–16,
2025
Location:
San
Francisco,
California,
USA
Event
Website:
https://ddsswc.agilefalconsg.com/